Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 218 of the 218 references it cites were found in a registry or an index; 23 of the 292 sources its claims cite were checked for support.

Global health 2050: the path to halving premature death by mid-century

Open access

Abstract

Executive summary Global health 2050 (GH2050), a new report from the Lancet Commission on Investing in Health, finds that dramatic improvements in human welfare are achievable by mid-century with focused health investments. By 2050, countries that choose to do so can halve their probability of premature death (PPD)—the probability of dying before age 70—from their pre-pandemic level in 2019. We call this goal “50 by 50”: a 50% reduction in PPD by 2050. The interventions for achieving “50 by 50” will also reduce morbidity and disability at all ages. Historical experience and continued scientific advance indicate that this is a feasible aspiration. Eight of the 30 most populous countries reduced their PPD over the last decade at a rate that would halve PPD before 2050, including countries as diverse as Bangladesh, Iran, Tanzania, and Turkey. These focused gains can be achieved relatively early on the pathway to full universal health coverage (UHC). The path to achieving “50 by 50” runs through control of a remarkably narrow set of just 15 conditions. For currently high mortality countries, eight infectious diseases and maternal conditions are the highest priority. Seven clusters of noncommunicable diseases and injuries are important everywhere and addressing them will prove central to achieving “50 by 50” in most countries with lower initial levels of mortality. Focused attention to health system strengthening (HSS) for primary care and first level hospitals will generate capacity to better tackle the 15 priority conditions and will be a critical step on the way to improving capacity to address all the conditions in a UHC package. Packaging interventions into 19 modules (e.g., a childhood immunization module, a module on cardiovascular disease prevention and low-cost, widely available treatment) will address the 15 priority conditions. Adopting this focused approach also invests in key areas of HSS and addresses major morbidities, such as psychiatric illness, not already covered by mortality-reducing interventions. Value for money can be assessed through a two-step process: technical cost effectiveness to assess how best to achieve module-specific goals (e.g., reduction in child mortality, reduction in cardiovascular mortality) and political evaluation of trade-offs in investing in expanding module coverage. In many countries seeking reform, standard budgetary mechanisms have failed to successfully reorient systems toward priority interventions that improve health. This mechanism of blanket budget transfers from ministries of finance to ministries of health has not been fit to support such reorientation. The Commission concluded that this problem could be addressed by directing a substantial and increasing fraction of budget transfers to making available and affordable the specific drugs, vaccines, diagnostics, and other commodities that are currently available for control of the 15 priority conditions. Drug availability and affordability will typically require four complementary components: (i) redirecting general budget transfers to line item transfers (subsidies) for specific priority drugs; (ii) centralized procurement by government (or perhaps internationally); (iii) procurement in sufficient volumes to ensure availability when needed; and (iv) use and strengthening of existing supply chains, public and private. Of the many intersectoral policies that governments can adopt to help achieve “50 by 50,” tobacco control is by far the most important, given the number of deaths caused by tobacco and the established and improving capacity of governments to implement tobacco policy. A high level of tobacco taxation is essential, and valuable in the short to medium term for public finance, and should be accompanied by a package of other effective tobacco control policies. Background research conducted for the Commission points to exceptionally high ongoing levels of mortality risk from pandemics. Country performance against COVID-19 varied greatly, although eventual vaccine availability attenuated, but far from eliminated, this variability by the end of COVID-19’s emergency phase. National implementation of public health fundamentals—early action, isolation of infected individuals, quarantining of those exposed, and social and financial support for people isolating or quarantining—accounted for much of the success of the best-performing nations, such as Japan. In the next pandemic, these fundamentals will help to avert mortality while waiting for vaccine development and deployment. The conclusions above are primarily aimed at national governments. Our final conclusion is aimed at the development assistance community. We conclude that such assistance should focus on two broad purposes. The first is to provide direct financial and technical support to countries with the least resources—to help develop health systems to better control diseases. The second is to finance global public goods, including strengthening data systems; reducing the development and spread of antimicrobial resistance; preventing and responding to pandemics; fostering global health leadership and advocacy; identifying and spreading best practices; and developing and deploying new health technologies. For both purposes, focusing efforts on the 15 priority conditions would best contribute to “50 by 50.” A decade ago, there were no malaria vaccines and the only available tuberculosis vaccine had low efficacy. Today, two partially successful malaria vaccines have been approved and three promising tuberculosis vaccine candidates are in late stage trials. These successes exemplify the enormous value in funding development of new medicines, vaccines, diagnostics, and operational research against the 15 priority conditions. The prize of “50 by 50,” with an interim milestone of “30 by 2035” (a 30% reduction in PPD by 2035), remains a prize within reach. The most efficient route is to focus resources against a narrow set of conditions and scale up financing to develop and deploy new health technologies. Our economic analyses have shown that the value of achievable mortality declines remains high and indeed is often a substantial fraction of the value of gains in gross domestic product. Today, the case is better than ever for the value of investing in health for reducing mortality and morbidity, alleviating poverty, growing economies, and improving human welfare.

Overview

CoChat Summary

TL;DR

The Lancet Commission on Investing in Health’s GH2050 report argues that countries can halve their probability of premature death (PPD) by 2050 (“50 by 50”) from 2019 levels, with an interim “30 by 2035” milestone, by focusing on 15 priority conditions and health-system strengthening. It presents historical trends, modular cost-effectiveness and financing proposals, and pandemic-risk estimates to support this agenda.

Key findings

  • “50 by 50” and “30 by 2035”: global PPD was 31% in 2019, about half the early-1960s level of 62%; achieving “50 by 50” globally would imply a 15% chance of dying before age 70 in 2050, the North Atlantic’s 2019 level. Eight of the 30 most populous countries were on track from 2010–2019 to halve PPD by 2050, 37 countries had halved PPD in 31 years or less historically, and 33 countries had an annual PPD decline of at least 2.2% in 2010–2019.
  • The 15 priority conditions—eight infections/maternal conditions (I-8) and seven NCDs/injuries (NCD-7)—account for about 80% of the life expectancy gap between most regions and the North Atlantic (85% for China, 76% for sub-Saharan Africa) and about 86% of the global life expectancy increase from 2000–2019. The I-8 contributed 3.5 of the 6.3-year global gain; the NCD-7 contributed 1.9 years.
  • Tobacco control is called the most important intersectoral policy for “50 by 50”; a 100% tobacco price increase in low- and middle-income countries is associated with a 40% decline in consumption (about 20% quitting and 20% reducing daily use), and tobacco taxes are described as highly progressive. In 2022, only 40 countries (about 10% of the world’s population) enforced recommended tax rates of 75% or more of cigarette prices.
  • COVID-19 caused about 26 million excess deaths during January 2020–May 4, 2023, a global P-score of about 13%; future pandemic risk is estimated at 2.5 million expected annual deaths, with about even odds of a pandemic causing 25 million or more deaths between now and 2050. By 2050, low-income and lower-middle-income countries would need to spend 2.5% and 4.1% of current GDP, respectively, on the priority interventions, requiring additional spending of 1.1% and 2.0% of current GDP.

Methods

  • Design: third report of the Lancet Commission on Investing in Health, using probability of premature death (PPD) as the primary metric and examining global health trends from 1970–2023, with regional groupings, the 30 most populous countries, and 123 countries with populations greater than 5 million.
  • Data and analysis: draws on UN Population Division, WHO Global Health Estimates, World Bank, GBD, Economist excess-death estimates, and Commission background papers; analyses include life-table decomposition of life expectancy gaps by cause, feasibility projections for halving PPD, modular cost-effectiveness analysis, cost estimates for 63 low- and lower-middle-income countries, DAH+ tracking, and pandemic-risk simulations.
  • Main analysis: compares observed PPD decline rates against the 2.2% annual decline needed for “50 by 50,” decomposes gains by the 15 priority conditions, and estimates financing needs and delivery mechanisms for the proposed modular health-system-strengthening agenda.

Limitations

  • Stated: underlying economic, social, demographic, and health-system data have gaps and inaccuracies, especially in low- and lower-middle-income countries; COVID-19 excess deaths for 2022–2023 rely on Economist estimates with possible larger discrepancies; pandemic-risk and climate-mortality projections are highly uncertain; P-scores are early approximations; and cost estimates assume spending on existing services and commodities.
  • Stated: the modular approach and cost estimates are stylized and not a prescription for every country; local circumstances should dictate details, and not every module or intervention will be relevant everywhere.
  • Evident from the text: many analyses depend on background papers, modeling, and projections rather than new primary data collection, and several key estimates—including future pandemic risk, climate impacts, and financing needs—are explicitly approximate or uncertain.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)01439-9

Cites

218 of 218 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1: Map of CIH regions with basic statistics
Figure 1: Map of CIH regions with basic statisticsCC BY · PubMed Central
Figure 2: The probability of premature death, 1970–2019: World, China, India, North Atlantic, Sub-Saharan Africa, and the United States Note: The graph highlights the time taken for certain regions—namely the North Atlantic, China, the World, and India—to halve their PPD values to 2019 levels. Data from reference 14 14
Figure 2: The probability of premature death, 1970–2019: World, China, India, North Atlantic, Sub-Saharan Africa, and the United States Note: The graph highlights the time taken for certain regions—namely the North Atlantic, China, the World, and India—to halve their PPD values to 2019 levels. Data from reference 14 14CC BY · PubMed Central
Figure 3: Life expectancy (LE) versus health-adjusted life expectancy (HALE) Source from reference 14 14 Data from reference 15 15
Figure 3: Life expectancy (LE) versus health-adjusted life expectancy (HALE) Source from reference 14 14 Data from reference 15 15CC BY · PubMed Central
Figure 4: Country performance on the probability of premature death – level relative to per capita income, and halving time, world’s 30 most populous countries, 2019 Notes: 1. PPD is the probability of premature death, i.e., death before age 70. World average PPD was 31% in 2019. 2. The y-axis values show the number of years required to halve a country’s PPD if its rate of improvement in 2010–19 were to continue. The horizontal line drawn at 31 years indicates a halving time just adequate to reduce premature mortality by 50% between 2019 and 2050. Values above 75 years are simply indicated as ‘greater than 75’. 3. The x-axis values show a country’s deviation from the PPD that would be predicted from its income in 2019. The 2019 PPD for Italy, to take an example, was 12 and its value predicted from income was 17. Since predicted is higher than actual, the deviation is a favorable −5.
Figure 4: Country performance on the probability of premature death – level relative to per capita income, and halving time, world’s 30 most populous countries, 2019 Notes: 1. PPD is the probability of premature death, i.e., death before age 70. World average PPD was 31% in 2019. 2. The y-axis values show the number of years required to halve a country’s PPD if its rate of improvement in 2010–19 were to continue. The horizontal line drawn at 31 years indicates a halving time just adequate to reduce premature mortality by 50% between 2019 and 2050. Values above 75 years are simply indicated as ‘greater than 75’. 3. The x-axis values show a country’s deviation from the PPD that would be predicted from its income in 2019. The 2019 PPD for Italy, to take an example, was 12 and its value predicted from income was 17. Since predicted is higher than actual, the deviation is a favorable −5.CC BY · PubMed Central
Figure 5: Percent change in income, value of mortality change, full income in France and the United States from 2000–2019 Source from reference 20 20
Figure 5: Percent change in income, value of mortality change, full income in France and the United States from 2000–2019 Source from reference 20 20CC BY · PubMed Central
Figure 6: Projected increase in annual heat-related deaths due to climate change compared to the 2015 baseline Note: The graph presents estimates under two Representative Concentration Pathways (RCPs): RCP 4.5, a ~2.4°C increase in global temperatures by 2100 compared to 1850–1900, and RCP 8.5, a ~4.3°C increase, as per the IPCC Fifth Assessment Report from reference 42.42 As of 2024, global temperatures have already risen between 1.25°C and 1.5°C from 1850–1900 (Hausfather, 2024). Source from projections adapted from reference 37 37
Figure 6: Projected increase in annual heat-related deaths due to climate change compared to the 2015 baseline Note: The graph presents estimates under two Representative Concentration Pathways (RCPs): RCP 4.5, a ~2.4°C increase in global temperatures by 2100 compared to 1850–1900, and RCP 8.5, a ~4.3°C increase, as per the IPCC Fifth Assessment Report from reference 42.42 As of 2024, global temperatures have already risen between 1.25°C and 1.5°C from 1850–1900 (Hausfather, 2024). Source from projections adapted from reference 37 37CC BY · PubMed Central
Figure 7: Global and frontier probability of premature death (PPD), 1950–2021 Note: Probability of premature death (PPD) was defined as dying before age 70 years. The frontier is the lowest PPD ever observed. Countries with a population below 3 million in 2019 were not considered for being a frontier. Data source from reference 11 11. Source from reference 79 79
Figure 7: Global and frontier probability of premature death (PPD), 1950–2021 Note: Probability of premature death (PPD) was defined as dying before age 70 years. The frontier is the lowest PPD ever observed. Countries with a population below 3 million in 2019 were not considered for being a frontier. Data source from reference 11 11. Source from reference 79 79CC BY · PubMed Central
Figure 8: Seven high-population countries that achieved a halving of PPD in the last half century over 31 years or less Notes: PPD = Probability of premature death Source from reference 14 14 Data source from reference 11 11
Figure 8: Seven high-population countries that achieved a halving of PPD in the last half century over 31 years or less Notes: PPD = Probability of premature death Source from reference 14 14 Data source from reference 11 11CC BY · PubMed Central
Figure 9: Sex differences in the rate of decline in PPD, 30 most populous countries, 2010–19 Source from UN World Population Prospects 2024
Figure 9: Sex differences in the rate of decline in PPD, 30 most populous countries, 2010–19 Source from UN World Population Prospects 2024CC BY · PubMed Central
Figure 10: Life expectancy gap compared to the North Atlantic region attributable to priority conditions, 2019 Note: Life expectancy in the North Atlantic was 82 years in 2019. The priority conditions are I-8 plus the NCD-7, as defined below. The priority infections and maternal health conditions (I-8) are neonatal conditions, lower respiratory infections, diarrheal diseases, HIV/AIDS, tuberculosis, malaria, childhood-cluster diseases and maternal conditions. The priority NCDs and injuries (NCD-7) are atherosclerotic cardiovascular diseases, hemorrhagic stroke, NCDs strongly linked to infections, NCDs strongly linked to tobacco use, diabetes, road injury and suicide. Source from reference 80 80 Data from reference 11 and 15.11,15
Figure 10: Life expectancy gap compared to the North Atlantic region attributable to priority conditions, 2019 Note: Life expectancy in the North Atlantic was 82 years in 2019. The priority conditions are I-8 plus the NCD-7, as defined below. The priority infections and maternal health conditions (I-8) are neonatal conditions, lower respiratory infections, diarrheal diseases, HIV/AIDS, tuberculosis, malaria, childhood-cluster diseases and maternal conditions. The priority NCDs and injuries (NCD-7) are atherosclerotic cardiovascular diseases, hemorrhagic stroke, NCDs strongly linked to infections, NCDs strongly linked to tobacco use, diabetes, road injury and suicide. Source from reference 80 80 Data from reference 11 and 15.11,15CC BY · PubMed Central
Figure 11: Life expectancy gap compared to the North Atlantic attributable to individual I-8, 2019 Note: Life expectancy in the North Atlantic was 82 years in 2019. The full bars show the total life expectancy gap. Red parts show life expectancy gap accounted for by the cause indicated on the y-axis. Green+red parts show the cumulative contribution of the causes indicated at and above each bar on the y-axis to gap. Gray part shows the proportion not accounted for. Source from reference 80 80 Data from reference 11 and 15 11,15
Figure 11: Life expectancy gap compared to the North Atlantic attributable to individual I-8, 2019 Note: Life expectancy in the North Atlantic was 82 years in 2019. The full bars show the total life expectancy gap. Red parts show life expectancy gap accounted for by the cause indicated on the y-axis. Green+red parts show the cumulative contribution of the causes indicated at and above each bar on the y-axis to gap. Gray part shows the proportion not accounted for. Source from reference 80 80 Data from reference 11 and 15 11,15CC BY · PubMed Central
Figure 12: Life expectancy gap compared to the North Atlantic attributable to individual NCD7, 2019 Note: Life expectancy in the North Atlantic was 82 years in 2019. The full bars show the total life expectancy gap. Red parts show life expectancy gap accounted for by the cause indicated on the y-axis. Blue+red parts show the cumulative contribution of the causes indicated at and above each bar on the y-axis to gap. Gray part shows the proportion not accounted for. Source from reference 80 80 Data from references 11 and 35 11,15
Figure 12: Life expectancy gap compared to the North Atlantic attributable to individual NCD7, 2019 Note: Life expectancy in the North Atlantic was 82 years in 2019. The full bars show the total life expectancy gap. Red parts show life expectancy gap accounted for by the cause indicated on the y-axis. Blue+red parts show the cumulative contribution of the causes indicated at and above each bar on the y-axis to gap. Gray part shows the proportion not accounted for. Source from reference 80 80 Data from references 11 and 35 11,15CC BY · PubMed Central
Figure 13: Hemorrhagic stroke, sources of change in deaths from 2000 to 2019, ages 50–69, by CIH region Note: Mortality rate in year 2000 is expressed per 100,000 population per year. Negative rate of change in the figure indicates decline and a positive rate of change indicates increase.
Figure 13: Hemorrhagic stroke, sources of change in deaths from 2000 to 2019, ages 50–69, by CIH region Note: Mortality rate in year 2000 is expressed per 100,000 population per year. Negative rate of change in the figure indicates decline and a positive rate of change indicates increase.CC BY · PubMed Central
Figure 14: Prevalence of stunting among females in selected countries
Figure 14: Prevalence of stunting among females in selected countriesCC BY · PubMed Central
Figure 15: Mathematics test scores relative to Singapore, PISA 2022, selected countries Source from reference 84 84
Figure 15: Mathematics test scores relative to Singapore, PISA 2022, selected countries Source from reference 84 84CC BY · PubMed Central
Figure 16: Current levels of government tax revenue and health spending, by country Note: Data are from the reference 145.145 The most recent values for each country with complete data (n=126) are plotted here.
Figure 16: Current levels of government tax revenue and health spending, by country Note: Data are from the reference 145.145 The most recent values for each country with complete data (n=126) are plotted here.CC BY · PubMed Central
Figure 17: Crude death rate, 1990–2021 and projections to 2050 Note: COVID-19 years (2020–2022) were omitted. Working age is defined as ages 15–64 years. Data Source from reference 11 11
Figure 17: Crude death rate, 1990–2021 and projections to 2050 Note: COVID-19 years (2020–2022) were omitted. Working age is defined as ages 15–64 years. Data Source from reference 11 11CC BY · PubMed Central
Figure 18: P-score by month: Italy, United States, India and Japan — April 2020 to October 2023 Note: The graph highlights the time taken for certain regions—namely the North Atlantic, China, the World, and India—to halve their PPD values to 2019 levels. Data source: Excess deaths data were downloaded from Our World in Data. Projected deaths were based on deaths in 2019 and the annual change (averaged between 2015–2019) from reference 35 11. Annual projected deaths were divided by 12 (i.e., death baseline were assumed to be uniform across each year). P-Scores were calculated by dividing excess deaths by the projected deaths.
Figure 18: P-score by month: Italy, United States, India and Japan — April 2020 to October 2023 Note: The graph highlights the time taken for certain regions—namely the North Atlantic, China, the World, and India—to halve their PPD values to 2019 levels. Data source: Excess deaths data were downloaded from Our World in Data. Projected deaths were based on deaths in 2019 and the annual change (averaged between 2015–2019) from reference 35 11. Annual projected deaths were divided by 12 (i.e., death baseline were assumed to be uniform across each year). P-Scores were calculated by dividing excess deaths by the projected deaths.CC BY · PubMed Central
Figure 19: Framework for the phases of the pandemic cycle
Figure 19: Framework for the phases of the pandemic cycleCC BY · PubMed Central
Figure 20: ODA+: Evolution of DAH+ disbursements, 2013–2022 Notes: Gross disbursements. Constant 2021 prices (USD billions). Sources: The CIH uses the term DAH+ to refer to official development assistance (ODA) for health and private (philanthropic) development finance to health as defined by the Organisation for Economic Cooperation and Development (OECD)’s Development Assistance Committee (DAC). DAH+ also includes donor funding for neglected disease product development. Data for our DAH+ analysis comes from two sources: the OECD DAC’s Creditor Reporting System (CRS) database, and the Global Funding for Innovation for Neglected Diseases (G-FINDER) database. See also: reference 50 50
Figure 20: ODA+: Evolution of DAH+ disbursements, 2013–2022 Notes: Gross disbursements. Constant 2021 prices (USD billions). Sources: The CIH uses the term DAH+ to refer to official development assistance (ODA) for health and private (philanthropic) development finance to health as defined by the Organisation for Economic Cooperation and Development (OECD)’s Development Assistance Committee (DAC). DAH+ also includes donor funding for neglected disease product development. Data for our DAH+ analysis comes from two sources: the OECD DAC’s Creditor Reporting System (CRS) database, and the Global Funding for Innovation for Neglected Diseases (G-FINDER) database. See also: reference 50 50CC BY · PubMed Central
Figure 21: Total ODA disbursements to Ukraine and Sub-Saharan Africa Notes: Disbursements. Constant price in 2022 (USD millions). p= Preliminary figures. Source from reference 267 267
Figure 21: Total ODA disbursements to Ukraine and Sub-Saharan Africa Notes: Disbursements. Constant price in 2022 (USD millions). p= Preliminary figures. Source from reference 267 267CC BY · PubMed Central
Figure 22: Country-specific funding for the I-8 conditions Notes: Gross disbursements. Constant 2021 prices (USD) Source from reference 50 50
Figure 22: Country-specific funding for the I-8 conditions Notes: Gross disbursements. Constant 2021 prices (USD) Source from reference 50 50CC BY · PubMed Central

Verification

Claims the paper makes

19 Valid · 40 Not valid · 243 Not checked · 330 Own results and interpretations

291 more claims · 7 with their cited sources checked

Create a free account to see all 632 claims and to verify the 213 references still open.

See all claims — free account
  • Probably not a substantial claim. 210
  • It may state two separate claims as one. 188

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 197 references

Cited by

See all 125

Metadata

Authors
Jamison, D. T., Summers, L. H., Chang, A. Y., Karlsson, O., Mao, W., Norheim, O. F., Ogbuoji, O., Schäferhoff, M., Watkins, D., Adeyi, O., Alleyne, G., Alwan, A., Anand, S., Belachew, R., Berkley, S. F., Bertozzi, S. M., Bolongaita, S., Bundy, D., Bustreo, F., Castro, M. C., Chen, S., Fan, V. Y., Fawole, A., Feachem, R., Gebremedhin, L., Ghosh, J., Goldie, S. J., Gonzalez-Pier, E., Guo, Y., Gupta, S., Jha, P., Knaul, F. M., Kruk, M. E., Kurowski, C., Liu, G. G., Makimoto, S., Mataria, A., Nugent, R., Oshitani, H., Pablos-Mendez, A., Peto, R., Sekhri Feachem, N., Reddy, S., Salti, N., Saxenian, H., Seyi-Olajide, J., Soucat, A., Verguet, S., Zimmerman, A., & Yamey, G.
Affiliations
  • University of California, San Francisco (US)
  • Harvard University (US)
  • University of Southern Denmark (DK)
  • Duke University (US)
  • University of Bergen (NO)
  • University of Washington (US)
  • World Health Organization Regional Office for the Americas (US)
  • World Health Organization Regional Office for the Eastern Mediterranean (EG)
  • Stanford Medicine (US)
  • Government of Ethiopia (ET)
  • Brown University (US)
  • University of California, Berkeley (US)
  • London School of Hygiene & Tropical Medicine (GB)
  • Heidelberg University (DE)
  • Center for Global Development (US)
  • University of Massachusetts Amherst (US)
  • Peking University (CN)
  • University of Toronto (CA)
  • World Bank (US)
  • Japan International Cooperation Agency (JP)
  • Tohoku University (JP)
  • University of Oxford (GB)
  • Public Health Foundation of India (IN)
  • American University of Beirut (LB)
  • Results for Development Institute (US)
  • Agence française de développement (FR)
Corresponding author
Yamey, Gavin
Venue
The Lancet
Publisher
Elsevier BV
Published
2024-10
Volume
404
Issue
10462
Pages
1561-1614
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4403384471
Cited by
125
References
197
Citations by year
2026: 55 · 2025: 62 · 2024: 8
FWCI
11.43
Type
journal article
Language
en
Update notices
erratum (2024-11-09)
Open access
Licence
Locations
  • The Lancet (acceptedVersion)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, other-oa)
  • PubMed Central (acceptedVersion, cc-by)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Bill and Melinda Gates Foundation
  • Japan International Cooperation Agency
  • Direktoratet for Utviklingssamarbeid
  • Deutsche Gesellschaft für Internationale Zusammenarbeit (W19-0015)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Global Health Care Issues
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Global Health and Epidemiology
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Global Maternal and Child Health
Keywords
premature mortality, health investment, universal health coverage, health system strengthening, primary care, non-communicable diseases, injuries, infectious diseases, maternal health, childhood immunization, cardiovascular disease prevention, value for money, health care budgeting, health care financing, disability, global health targets, health care reform

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global health 2050: the path to halving premature death by mid-century. https://app.cochat.ai/papers/10.1016/s0140-6736(24)01439-9
The paper
Jamison, D. T., Summers, L. H., Chang, A. Y., Karlsson, O., Mao, W., Norheim, O. F., Ogbuoji, O., Schäferhoff, M., Watkins, D., Adeyi, O., Alleyne, G., Alwan, A., Anand, S., Belachew, R., Berkley, S. F., Bertozzi, S. M., Bolongaita, S., Bundy, D., Bustreo, F., . . . Yamey, G. (2024). Global health 2050: the path to halving premature death by mid-century. The Lancet. https://doi.org/10.1016/s0140-6736(24)01439-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.